Home › Compare › BBIXF vs MRK

BBIXF vs MRK: Dividend Comparison 2026

BBIXF yields 1666.67% · MRK yields 2.81%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 BBIXF wins by $1839785666.20M in total portfolio value
10 years
BBIXF
BBIXF
● Live price
1666.67%
Share price
$0.12
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$1839785666.26M
Annual income
$1,645,561,548,268,653.00
Full BBIXF calculator →
MRK
Merck & Co. Inc.
● Live price
2.81%
Share price
$118.10
Annual div
$3.32
5Y div CAGR
32.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$57.7K
Annual income
$10,113.78
Full MRK calculator →

Portfolio growth — BBIXF vs MRK

📍 BBIXF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodBBIXFMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, BBIXF + MRK cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
BBIXF pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

BBIXF
Annual income on $10K today (after 15% tax)
$141,666.67/yr
After 10yr DRIP, annual income (after tax)
$1,398,727,316,028,355.00/yr
MRK
Annual income on $10K today (after 15% tax)
$238.95/yr
After 10yr DRIP, annual income (after tax)
$8,596.71/yr
At 15% tax rate, BBIXF beats the other by $1,398,727,316,019,758.20/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of BBIXF + MRK for your $10,000?

BBIXF: 50%MRK: 50%
100% MRK50/50100% BBIXF
Portfolio after 10yr
$919892833.16M
Annual income
$822,780,774,139,383.40/yr
Blended yield
89.44%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

BBIXF
No analyst data
Altman Z
-19.8
Piotroski
2/9
MRK
Analyst Ratings
24
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+8.8% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

BBIXF buys
0
MRK buys
8
PoliticianChamberTickerTypeAmountDate
Josh Gottheimer🏢 House$MRK▲ Buy$1,001 - $15,0002026-02-04
Michael McCaul🏢 House$MRK▼ Sell$15,001 - $50,0002026-01-13
Gilbert Cisneros🏢 House$MRK▲ Buy$1,001 - $15,0002025-12-19
Julie Johnson🏢 House$MRK▼ Sell$1,001 - $15,0002025-12-18
Julie Johnson🏢 House$MRK▼ Sell$1,001 - $15,0002025-11-13
Ro Khanna🏢 House$MRK▼ Sell$1,001 - $15,0002025-09-29
Val Hoyle🏢 House$MRK▼ Sell$1,001 - $15,0002025-09-23
Marjorie Taylor Greene🏢 House$MRK▲ Buy$1,001 - $15,0002025-08-28
Julie Johnson🏢 House$MRK▼ Sell$1,001 - $15,0002025-08-14
Gilbert Cisneros🏢 House$MRK▲ Buy$1,001 - $15,0002025-08-05
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricBBIXFMRK
Forward yield1666.67% ✓2.81%
Annual dividend / share$2.00$3.32 ✓
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%32.7% ✓
Portfolio after 10y$1839785666.26M ✓$57.7K
Annual income after 10y$1,645,561,548,268,653.00 ✓$10,113.78
Total dividends collected$1825787439.21M ✓$29.8K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: BBIXF vs MRK ($10,000, DRIP)

YearBBIXF PortfolioBBIXF Income/yrMRK PortfolioMRK Income/yrGap
1← crossover$177,367$166,666.67$11,213$373.04+$166.2K → BBIXF
2$2,952,503$2,762,720.66$12,667$512.06+$2.94M → BBIXF
3$46,139,686$42,980,507.73$14,439$708.14+$46.13M → BBIXF
4$677,098,258$627,728,794.51$16,640$988.16+$677.08M → BBIXF
5$9,333,745,461$8,609,250,324.41$19,432$1,394.07+$9333.73M → BBIXF
6$120,900,966,251$110,913,858,608.07$23,057$1,992.90+$120900.94M → BBIXF
7$1,472,054,345,780$1,342,690,311,890.92$27,889$2,894.79+$1472054.32M → BBIXF
8$16,853,789,214,559$15,278,691,064,574.45$34,518$4,286.29+$16853789.18M → BBIXF
9$181,517,867,281,133$163,484,312,821,554.84$43,912$6,494.35+$181517867.24M → BBIXF
10$1,839,785,666,259,465$1,645,561,548,268,653.00$57,714$10,113.78+$1839785666.20M → BBIXF

BBIXF vs MRK: Complete Analysis 2026

BBIXF — Stock

Bonus BioGroup Ltd., a biotechnology company, develops technology solutions to generate tissue-regenerating bone grafts. It develops tissue-regenerating bone grafts from cells derived from the patient's own cells for the treatment of skeletal disorders, such as bone trauma and arthritis. The company's products include BonoFill injectable bone graft that is suitable for bone repair applications, including jaw bone cysts; and BonoFill pre-designed bone graft, which is used to repair large and segmental bone defects. Its products in pipeline comprise bone grafts for maxillofacial and orthopedic applications; novel nanomaterials technology for tissue regeneration; and large vascularized bone grafts. The company was formerly known as Oceana Advanced Industries Ltd. and changed its name to Bonus BioGroup Ltd. Bonus BioGroup Ltd. was founded in 1981 and is based in Haifa, Israel.

Full BBIXF Calculator →

MRK — Healthcare

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Full MRK Calculator →
📬

Get this BBIXF vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

BBIXF vs SCHDBBIXF vs JEPIBBIXF vs OBBIXF vs KOBBIXF vs MAINBBIXF vs JNJBBIXF vs ABBVBBIXF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.